This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Regional enteritis and ulcerative colitis
  • /
  • Pharmacodynamic assessment of vedolizumab for the ...
Journal

Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.

Read time: 1 mins
Published:25th Mar 2020
Author: McLean LP, Cross RK.
Ref.:Expert Opin Drug Metab Toxicol. 2016 Apr 20. [Epub ahead of print]
DOI:10.1080/17425255.2016.1181171

Introduction: Vedolizumab is an anti-integrin approved for the treatment of Crohn's disease and ulcerative colitis. By binding the α4β7-integrin heterodimer, vedolizumab blocks leukocyte translocation into gastrointestinal tissue.

Areas Covered: This review discusses the chemistry, pharmacologic properties, clinical efficacy, and safety of vedolizumab in ulcerative colitis. Other medications available for the treatment of ulcerative colitis are also discussed.

Expert Opinion: Vedolizumab is a promising new agent for the treatment of ulcerative colitis. Its mechanism of action differs from TNF-α inhibitors and immune suppressants, allowing it to be used in cases of TNF-α inhibitor failure or non-response, or as a first-line biologic drug. Available safety data suggests that vedolizumab is not associated with an increased risk of infection or malignancy; however, additional post-marketing data are required to confirm these initial reports. Vedolizumab is likely to be used in growing numbers of patients over the coming years.

Read abstract on library site